Related Experiment Video
Updated: May 12, 2026
07:02
Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
Published on: May 11, 2018
SMA-MAP: a plasma protein panel for spinal muscular atrophy
Dione T Kobayashi1, Jing Shi, Laurie Stephen
1Spinal Muscular Atrophy Foundation, New York, New York, United States of America. dkobayashi@smafoundation.org
Plos One
|April 9, 2013
Summary
Researchers discovered and validated new biomarkers for Spinal Muscular Atrophy (SMA), identifying a panel (SMA-MAP) to monitor disease activity and aid in therapy development for this neuromuscular condition.
Area of Science:
- Biomarker discovery and validation in neuromuscular diseases.
- Translational research in rare genetic disorders.
Background:
- Spinal Muscular Atrophy (SMA) diagnosis and progression monitoring are challenging.
- There is a need for validated biomarkers to assess SMA disease activity and treatment efficacy.
Purpose of the Study:
- To discover novel SMA biomarkers using immunoassay.
- To validate these biomarkers in an independent cohort of SMA patients.
- To develop a comprehensive biomarker panel for SMA.
Main Methods:
- Analyzed plasma samples from the Biomarkers for SMA (BforSMA) study using immunoassays.
- Selected 35 candidate biomarkers for validation in an independent SMA Natural History Study (NHS) cohort.
- Assessed biomarker association with motor function, pulmonary function, and quality of life measures.
Main Results:
- 12 of 35 candidate biomarkers showed significant association with SMA motor function.
- Additional analytes correlated with non-motor SMA outcomes.
- A panel of 27 analytes, named SMA-MAP, was generated for further evaluation.
Conclusions:
- Validated SMA biomarkers associated with motor function and disease activity.
- The SMA-MAP panel offers potential for use in clinical trials and monitoring SMA.
- Future research will explore the panel's utility in other neuromuscular diseases and therapeutic studies.
Related Concept Videos
01:21Satellite Stem Cells and Muscular Dystrophy
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...